Background: Several randomized trials performed in the era of original glycoprotein inhibitors (GP IIb/IIIa) showed a reduction in major adverse cardiac events when compared with placebo in a wide variety of percutanous coronary intervention (PCI) settings. Methods: This prospective study included 100 consecutive patients with acute St segment elevation myocardial infarction within 12 hr of onset of symptoms. All patients underwent primary PCI and were divided into two groups; Group 1 who received bolus plus infusion and group 2 who received bolus only GP IIb/IIIa inhibitors in the setting of PPCI. In-hospital mortality, reinfarction, bleeding and stroke were reported in all patients. Results: Primary end point was reported in 54% of patients in group 1 Vs 38% in group 2 (p=0.108), minor bleeding occurred in 12% of all patients (18% versus 6% in group 1,2 respectively, P =0.065), major bleeding occurred in 1% of all patients(2% versus 0% in group 1,2 respectively, P =0.315). Conclusion: The results of the current study suggest that bolus-only GPI is not inferior to bolus followed by 24- hours infusion as regard short term outcome with a trend for fewer mortality and bleeding complication rate.
|
